Quick Takeaways
- Catherine A. Sohn has 6 issuer positions tracked on this page.
- Estimated disclosed ownership value: $2,340,976.
- Recent insider filing activity is available below.
Insider Trading & Ownership of Catherine A. Sohn
- Location
- Gaithersburg, MD
- Summary
- The estimated net worth of Catherine A. Sohn is at least $2,340,976 dollars as of 01 May 2026. Catherine A. Sohn is the Director of Jazz Pharmaceuticals plc and owns shares of Jazz Pharmaceuticals plc (JAZZ) stock worth about $1.77M. Catherine A. Sohn is the Director of LANDEC CORP \CA\ and owns shares of LIFECORE BIOMEDICAL, INC. \DE\ (LFCR) stock worth about $563.4K. Catherine A. Sohn is the Director of Altimmune, Inc. and owns shares of Altimmune, Inc. (ALT) stock worth about $6.4K.
- Signature
- /s/ Gregory Weaver, as Attorney-in-Fact
- All Insider Reports
- All Insider Reports
Follow Filing Activity
Follow Catherine A. Sohn and return when a new Insider Trading filing changes the record on this page.
This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean.
What Changed
- Largest disclosed position: Jazz Pharmaceuticals plc ($1,771,225).
- Past-year value change for that position: .
Why This Matters
- This page translates Forms 3/4/5 into a quick ownership context before you inspect each transaction row.
- You can cross-check role, issuer, and filing chronology directly against the SEC source.
Source Evidence
Filed on Form 4
See Original Filing
Insider ownership context is sourced from SEC Forms 3, 4, and 5.
Ownership of Catherine A. Sohn
| Symbol | Company | Relationship | Holdings Value | Past Year Net Change | Change % | Report Period |
|---|---|---|---|---|---|---|
| JAZZ | Jazz Pharmaceuticals plc | Director | $1,771,225 | 11 Aug 2023 | ||
| LFCR | LANDEC CORP \CA\ | Director | $563,399 | 04 Jun 2022 | ||
| ALT | Altimmune, Inc. | Director | $6,352 | +$2,118 | +50% | 01 May 2026 |
| MAZE | Maze Therapeutics, Inc. | Director | $0 | -$1,149,054 | -100% | 06 Jan 2026 |
| AXLA | Axcella Health Inc. | Director | 19 May 2022 | |||
| RUBY | Rubius Therapeutics, Inc. | Director | 12 May 2022 |
Insider Transactions Reported by Catherine A. Sohn:
| Sym | Company | Class | Transaction | % | Value $ | * Price $ | Shares | Shares After | Date | Ownership |
|---|
* An asterisk sign (*) next to the price indicates that the price is likely invalid.